Selecta Biosciences, Inc. Long Term Debt (Total)

Long Term Debt (Total) of SELB for past 10 years: annual, quarterly and twelve month trailing (TTM) including Long Term Debt (Total) growth rates and interactive chart. Long-term debt is debt that matures in more than one year. The sum of long-term bank loans, debentures or bonds outstanding. Refers to interest-bearing debt. An indebted company pays interest on its debt, which is recorded on the income statement and reduces net income to common shareholders. Long-term debt is used in ratios lke Debt/Equity or Debt/Assets to determine the financial health of a business.


Highlights and Quick Summary

  • Long Term Debt (Total) for the quarter ending December 30, 2020 was $34.4 Million (a -0.1% decrease compared to previous quarter)
  • Year-over-year quarterly Long Term Debt (Total) increased by 229.89%
  • Annual Long Term Debt (Total) for 2020 was $34.4 Million (a 63.67% increase from previous year)
  • Annual Long Term Debt (Total) for 2017 was $21 Million (a 163.78% increase from previous year)
  • Annual Long Term Debt (Total) for 2016 was $7.98 Million (a -32.71% decrease from previous year)
Visit stockrow.com/SELB for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Long Term Debt (Total) of Selecta Biosciences, Inc.

Most recent Long Term Debt (Total)of SELB including historical data for past 10 years.

Interactive Chart of Long Term Debt (Total) of Selecta Biosciences, Inc.

Selecta Biosciences, Inc. Long Term Debt (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $34.44 $34.48 $16.57 $10.44 $34.44
2018 $21.21 $21.13
2017 $21.04 $20.95 $5.73 $6.87 $21.04
2016 $7.98 $9.06 $10.13 $7.98
2015 $11.86
2014 $4.82 $4.82

Business Profile of Selecta Biosciences, Inc.

Sector: Healthcare
Industry: Biotechnology
Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, researches and develops nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's proprietary pipeline includes enzymes therapies, gene therapies, and other products and product candidates affected by undesired immune responses. Its lead product is SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout, as well as develops a product candidate to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and IgA vasculitis. The company also engages in the development of gene therapy product candidates that are in preclinical development, including MMA-101, a product candidate for the treatment methylmalonic academia; SEL-313, a product candidate to treat ornithine transcarbamylase deficiency; SEL-399, a product candidate to indicate appropriate dose of ImmTOR in humans to reduce the formation of antibodies to AAV capsids; and other products for the treatment of pompe disease, duchenne muscular dystrophy, and limb-girdle muscular dystrophy. In addition, it develops a product candidate to treat primary biliary cholangitis. The company has license and collaboration agreements with Swedish Orphan Biovitrum; Spark Therapeutics; Massachusetts Institute of Technology; Shenyang Sunshine Pharmaceutical Co., Ltd.; Asklepios BioPharmaceutical, Inc. Sarepta Therapeutics, Inc.; and IGAN Biosciences, Inc. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.